1026785-55-6 Usage
Uses
Used in Pharmaceutical Industry:
5-(3,3-diMethylbut-1-yn-1-yl)-3-(N-(4-hydroxycyclohexyl)-4-MethylcyclohexanecarboxaMido)thiophene-2-carboxylic acid is used as a potential pharmaceutical compound for its unique structural features that may contribute to the development of new drugs. Its specific functional groups could be leveraged to target various biological pathways or to enhance drug delivery mechanisms.
Used in Organic Synthesis:
In the field of organic synthesis, 5-(3,3-diMethylbut-1-yn-1-yl)-3-(N-(4-hydroxycyclohexyl)-4-MethylcyclohexanecarboxaMido)thiophene-2-carboxylic acid serves as a key intermediate or building block in the synthesis of more complex organic molecules. Its reactive sites and structural diversity make it a valuable component in creating novel chemical entities.
Used in Materials Science:
5-(3,3-diMethylbut-1-yn-1-yl)-3-(N-(4-hydroxycyclohexyl)-4-MethylcyclohexanecarboxaMido)thiophene-2-carboxylic acid is utilized in materials science for its potential to contribute to the development of new materials with unique properties. Its incorporation into polymers or other materials could lead to advancements in areas such as electronics, sensors, or advanced materials with tailored characteristics.
Note: The specific applications and reasons provided are speculative based on the compound's structural features and are meant to illustrate potential uses. Actual applications would depend on the outcomes of further research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1026785-55-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,6,7,8 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1026785-55:
(9*1)+(8*0)+(7*2)+(6*6)+(5*7)+(4*8)+(3*5)+(2*5)+(1*5)=156
156 % 10 = 6
So 1026785-55-6 is a valid CAS Registry Number.
1026785-55-6Relevant articles and documents
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection
Lazerwith, Scott E.,Lew, Willard,Zhang, Jennifer,Morganelli, Philip,Liu, Qi,Canales, Eda,Clarke, Michael O.,Doerffler, Edward,Byun, Daniel,Mertzman, Michael,Ye, Hong,Chong, Lee,Xu, Lianhong,Appleby, Todd,Chen, Xiaowu,Fenaux, Martijn,Hashash, Ahmad,Leavitt, Stephanie A.,Mabery, Eric,Matles, Mike,Mwangi, Judy W.,Tian, Yang,Lee, Yu-Jen,Zhang, Jingyu,Zhu, Christine,Murray, Bernard P.,Watkins, William J.
, p. 1893 - 1901 (2014/04/03)
Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure-activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.
